| INTRODUC TI ON
Clinical studies of human papillomavirus (HPV) virus-like particlebased vaccines have reported close to 100% protection against vaccine-type infection and its associated diseases in the per-protocol populations. 1, 2 In Japan, a bivalent vaccine against HPV16 and HPV18 was licensed in October 2009, and a quadrivalent vaccine against HPV6, HPV11, HPV16, and HPV18 was licensed in July 2011.
In Japan, routine (government-funded) HPV vaccination targets girls aged 12-16 years, and catch-up vaccination is recommended for young women up to age 26 years in the Japanese guidelines. 3 A government-funded HPV vaccination program began for girls aged 12-16 years as an urgent high-priority vaccination project in December 2010, and was incorporated into the National Vaccination Program in April 2013. However, the proactive recommendation for HPV vaccination by the government has been suspended since June 2013 because news reports on potential adverse effects of HPV vaccines appeared repeatedly in the media. 4, 5 Consequently, the immunization coverage among adolescent girls decreased quickly and dramatically throughout the country. 6 The coverage of HPV vaccines in Sapporo (Hokkaido, Japan) was high (70% for 3-dose completion) in female individuals born between 1994 and 1998, 30%-40% in those born in 1999, but very low (less than 1%) in those born in 2000 or later. 4 A similar decrease in HPV vaccine coverage was reported in Sakai (Osaka, Japan). 7 Suspension of the recommendation for vaccination has continued to the present, despite no scientific or epidemiologic evidence showing a causal link between postvaccination symptoms and HPV vaccines. 6, 8 This situation is unique to Japan.
To date, postlicensure evidence of vaccination against HPVrelated cervical diseases and genital warts at the population level has been reported in real-world settings. 9 In Australia, an ecological study has shown a decline in the rates of high-grade cervical lesions in targeted populations ahead of other countries. 10 Studies from Australia, the United States, and Scotland have also reported a significant reduction in the prevalence of vaccine-targeted HPV genotypes in vaccinated cohorts. [11] [12] [13] In Japan, a prospective cohort study reported a lower incidence of vaccine-type HPV16/18 infections among young vaccinated women. 14 
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K E Y W O R D S
adenocarcinoma in situ, cervical cancer, cervical intraepithelial neoplasia, human papillomavirus, vaccination cervical screening registries have reported lower incidences of abnormal cytology among women aged 20-24 years or vaccinated in the government-funded vaccination program. [15] [16] [17] [18] However, these studies were based on cytological data and did not evaluate vaccine type-specific effects on cervical diseases. Moreover, few studies have addressed the population effectiveness of catch-up vaccination in Japan.
To further evaluate the effectiveness of population-based HPV vaccination at an early date, we initiated a collaborative hospitalbased research study to monitor the long-term population-level impact of HPV vaccination (the MINT project) in Japan in 2012. 19 The final goal of the MINT project is to determine the vaccine effect on invasive cervical cancer (ICC) (ie, a significant reduction in the incidence of ICC and the number of deaths from ICC) in Japan.
However, given the long lead-time from HPV infections to development of ICC, a vaccination-related effect on ICC would take decades to be seen. By contrast, a decrease in HPV16/18-positive rates in cervical diseases is expected to occur more quickly and to thus be one of the earliest measures of vaccine impact. 20 Therefore, we selected HPV16/18 prevalence among young women newly diagnosed with cervical intraepithelial neoplasia grade 1-3 (CIN1-3), adenocarcinoma in situ (AIS), or ICC each year as the primary endpoint. This final analysis (n = 5045) of MINT study I included many more cases than our interim analysis (n = 2402). 21 In addition to updating our previous findings, the larger dataset enabled us to evaluate crossprotection efficacy against nonvaccine types and vaccine impact according to age at first vaccination. The MINT study is the first observation to report the vaccine type-specific impact of the routine and catch-up HPV vaccination on cervical abnormalities in Japan.
We hope that our findings will lead to resumption of vaccination recommendation by the Japanese government.
| MATERIAL S AND ME THODS

| Study design
We prospectively undertook a collaborative hospital-based study to monitor the long-term population-level impact of HPV vaccination in Japan. Details of the design and methods have been provided elsewhere. 19, 21 Briefly, study participants consist of all women aged 16-39 years (age at registration) newly diagnosed with ICC, CIN, or AIS, without a history of treatment for cervical diseases, at 21 participating institutions as from 2012. These institutes were recruited because they rank highly for the number of ICC cases regis- Unfortunately, the present study relied on self-reported information about vaccination status and official vaccination records were not available to ascertain vaccination status. Also, information on sexual history was not collected. This monitoring project was planned for a total period of 21 years, which was divided into 3 phases of 7 years each: phase I, August 2012 to December 2018; phase II, January 2019 to December 2025; and phase III, January 2026 to December 2032. 19 Phase I of this research (MINT study I) was originally planned from 2012 to 2018. However, a research grant obtained from the Foundation for Advancement of International Science was stopped in 2018. Therefore, we undertook a 6-year final analysis of the MINT I study (2012) (2013) (2014) (2015) (2016) (2017) .
The study participants are divided into the following 3 groups: category A, women newly diagnosed with ICC at participating facilities each year (registration and HPV genotyping test are necessary for all women diagnosed with ICC); category B, women newly diagnosed with CIN2-3 or AIS (registration is necessary for all women diagnosed with CIN2-3 or AIS; however, HPV genotyping tests were carried out until the total number of participants tested reaches 600); and category C, women newly diagnosed with CIN1 (each year, registration and HPV genotyping are carried out until the total number of subjects tested at all facilities reaches 100). In addition, the number of women treated for ICC within the previous 10 years at participating institutes who die from the disease is also monitored each year (HPV genotyping test will not be carried out).
In the MINT project, the primary endpoint of phase I is the propor- Amplicons were subjected to reverse line blot hybridization for detection of 37 individual HPV genotypes (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51 to 56, 58, 59, 61, 62, 64, 66 to 73, 81-84, 82v, and 89). Linear Array does not directly detect HPV52 but combines a set of probes that detects HPV33, 35, 52, and 58 combined (HPVmix). Specimens that tested negative for HPV33, 35, and 58 individually but were positive for the HPVmix were considered to be HPV52 positive. Thus, LA cannot discriminate HPV52 infection when it is co-infected with HPV33, 35, and 58, suggesting that HPV52 prevalence might be underestimated in the present study.
| Human papillomavirus genotyping procedures
All of the HPV DNA assays were carried out by individuals who were masked to the results in the clinical profile of each project. 
| Statistical methods
| RE SULTS
A total of 7709 women aged less than 40 years who were newly diagnosed with CIN1 (n = 589), CIN2-3/AIS (n = 5828), or ICC (n = 1292) at the 21 participating institutes were registered between 2012 and 2017. Because we started the present study in August 2012, the number of study participants was smaller in 2012 than in other years. For CIN2-3/AIS and ICC, although all cases diagnosed with these diseases at the 21 participating institutes were registered, we could not find any significant trends in the number of cases in women aged 20-24 years between 2013 and 2017 ( Figure 1 ).
We obtained HPV type-specific data from 5045 women (CIN1, n = 573; CIN2-3/AIS, n = 3342; ICC, n = 1130). In the present study, HPV genotyping assays were undertaken for CIN1 and CIN2-3/ AIS until the total number of samples tested reached 100 and 600 each year, respectively. Although all ICC cases were to be tested for HPV genotype, HPV typing results were lacking among 162 early stage ICC cases because of ICC diagnosis after conization; their characteristics are summarized in Table 1 . The mean age ± SD of study participants was 32.4 ± 4.6 years: 30.6 ± 5.3 years for CIN1, 32.1 ± 4.6 years for CIN2-3/AIS, and 34.0 ± 3.8 years for ICC.
Among women younger than 25 years, HPV16/18 prevalence decreased from 50.0% to 0.0% in CIN1 (P trend < .0001 Figure 2A) and from 83.3% to 45.0% in CIN2-3/AIS (P trend = .07, Figure 2B women that developed HPV16/18-positive CIN2-3/AIS (n = 2) or ICC (n = 1) following routine HPV vaccination. We note that these women were born in 1994 and aged 16 years at first vaccination, but no information about their sexual history was available.
We also addressed the effectiveness of HPV vaccinations according to age at first vaccination. The youngest age at the time of first vaccination was 13 years. The HPV16/18 prevalence in CIN2-3/ AIS was 12.5% for women who received their first dose at ages We also evaluated the prevalence of nonvaccine HPV types HPV31, HPV33, HPV45, HPV52, and HPV58 between vaccinated and unvaccinated women ( Table 2 ). The prevalence of HPV52 and HPV58 in cervical lesions was higher among vaccinated women than among unvaccinated ones (37.9% vs 27.8% for CIN1 and 44.3% .007
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| D ISCUSS I ON
In this study, declining proportions of HPV16/18-positive CIN/AIS lesions among vaccinated cohorts provided more specific evidence than previous studies reporting a declining incidence of abnormal Pap results among young women in Japan. [15] [16] [17] [18] In addition, we also found that HPV vaccination was significantly effective against Among vaccinated women, attribution of HPV16 and HPV18 to CIN2-3/AIS was significantly lower among those aged 13-20 y at first vaccination than among those aged >20 y at first vaccination (P = .02) multiple age-cohort and gender-neutral vaccination programs and very high vaccination coverage, catch-up vaccination with 3 doses significantly protected against high-grade cervical lesions among women aged 15-18 and 19-22 years at first vaccination, but not among women aged 23-27 years at first vaccination. 23 In Scotland, with girls-only vaccination and high uptake, protective effect of 3-dose catch-up vaccination against CIN2+ was significant among women first vaccinated at age 14-17 years, but not among women first vaccinated at age 18 years or older. 24 These differences could be explained in part by differences in vaccine herd effects (ie, reduced transmission of HPV infections) between countries. A recent meta-analysis found that HPV immunization programs with multiple age-cohort vaccination and high vaccination coverage contribute to herd protection. 9 Therefore, the age range of women who benefit from catch-up vaccination might be country-specific.
The effectiveness of catch-up vaccination for women older than 21 years is one of the most important issues in HPV vaccination, especially in Japan, because the vaccination rate in women born in or after 2000 is extremely low (less than 1%). [4] [5] [6] [7] Therefore, additional studies will be warranted to confirm the limited effectiveness of catch-up vaccination in women older than 20 years.
We also evaluated the efficacy against nonvaccine HPV types Long-term changes in the number of women diagnosed with CIN2-3/ AIS or ICC, those receiving hysterectomy for these diseases, and deaths from ICC and positive rates for vaccine types and nonvaccine types will also be monitored. We will be able to assess whether the HPV vaccination "crisis" in Japan might again raise the HPV16/18 prevalence among young women. 8, 9 Sexual history information, such as age at first sex, will be collected in MINT study II.
In conclusion, the present study provided the first information 
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